



# Evaluating Efficacy of Hounsfield Unit measurement in Predicting Risk of Acute cerebral Venous Sinus Thrombosis on The single non-Enhanced CT brain

1. Dr. Puneeth Kumar K.N MD, DNB, MNAMS, 2. Dr. Padma Badhe MD, 3. Dr. Anuja Kapadnis MD, 4. Dr. Sanjeev H MD, 5. Dr. Pradeep MD

1,5- Assistant Professor, Department of Radiology, Saphthagiri institute of medical sciences and research centre, Bangalore -90.

2- Professor, Department of Radiology, Seth GS medical college and KEM Hospital, Mumbai -12

3- Senior Resident, Department of Radiology, Seth GS medical college and KEM Hospital, Mumbai -12

4- Senior Resident, Department of Radiology, Saphthagiri institute of medical sciences and research centre, Bangalore -90.

Submitted: 05-06-2021

Revised: 18-06-2021

Accepted: 20-06-2021

## I. INTRODUCTION

Cerebral venous thrombosis (CVT) is an uncommon condition, which over the past 5 to 10 years has been diagnosed due to rising clinical awareness and the availability of better non-invasive diagnostic techniques<sup>[1]</sup>. Cerebral vein and cerebral dural sinus thrombosis (CVT) is not a common cause for stroke than other types but it may be more challenging to diagnose. Because of its nonspecific presentation as well as its many predisposing causes CVT is an elusive diagnosis.

There is no study in the literature based on the population of India stating exact incidence of acute CVT. There are many hospital-based studies regarding CVT published in India. In the late 1970s, there is a hospital-based study from Northern India in which frequency of CVT is 4.5/1000 in obstetric admissions<sup>[2]</sup>. In the late 1960s, another population-based study from Southern India found that 25% of stroke patients were less than (<) 40 years of age and were primarily young women having a CVT which had occurred in the postpartum stage<sup>[3]</sup>.

Cerebral venous sinus thrombosis can affect any age group even neonates with a younger age at distribution than arterial stroke. It affects females more than males, particularly in the age group of 20 to 35, due to pregnancy, puerperium and oral contraceptive use. Mean age in most larger studies was between 37 and 38 years though all ages can be affected<sup>[4][5]</sup>.

Dural venous sinus thrombosis commonly affects the superior sagittal sinus (SSS) and/or the transverse sinuses<sup>[6]</sup>.

There are many pathophysiological mechanisms and predisposing risk factors like hypercoagulable state, dehydration or pregnancy, the postpartum state, extrinsic compression or local invasion of a

vein by tumor or an adjacent infectious process (e.g., mastoiditis), a slow-flow state within the venous sinus, and or dural sinus compression<sup>[7][8]</sup>.

There is also a wide distribution in the mode of onset of symptoms, with approximately 28% acute (<48 hours), 42% subacute (between 48 hours and 30 days), and 30% chronic (>30 days)<sup>[6]</sup>.

Treatment strategies are aimed to control or reverse the underlying pathology, controlling ICH and treatment of seizures or focal deficits caused by cerebral edema or infarction<sup>[12]</sup>.

Because of its varied causes and presentations, CVT is a disease that may be encountered by neurologists and neurosurgeons as well as by emergency

clinicians, internists, oncologists, hematologists, obstetricians, pediatricians, and family practitioners. In every neuro-radiologic case, the evaluation for evidence of CVT should be included in the diagnostic checklist.

The radiologist can be the first physician to suggest the diagnosis, which is a radiological and not merely a clinical. So imaging plays a key role in the diagnosis. The imaging findings are easily overlooked if not specifically sought.

Though angiography is still considered to be the 'gold standard', MRI and MR venography is currently the preferred technique for making the diagnosis of CVT. MR imaging has been reported to have advantages over CT and conventional angiography and was advocated as the test of choice for the definitive diagnosis of dural sinus thrombosis<sup>[13,14]</sup>.

Conventional CT was the best noninvasive method of diagnosing CVT before the discovery of MRI<sup>[1]</sup>.

CT venography is a very rapid, readily available and accurate technique for detecting cerebral venous thrombosis<sup>[15][16]</sup>. CT venography provides



a highly detailed view of the cerebral venous system, superior to that available with conventional TOF MR venography, and has at least similar accuracy for the detection of cerebral venous thrombosis<sup>[15]</sup>.

In the present era, CT is the first modality of choice for investigating most neurological conditions. CT is likely to remain the first or initial modality because of its widespread availability, comparatively less expensive and lower cost.

CT images are made up of pixels, each of which has a gray scale value from 1 (black) to 256 (white). This value corresponds to the number of X-rays that pass through

the structure and can be measured and expressed in Hounsfield units (HU).

HU has since been used to evaluate and quantify tissues and fluids. At standard pressure and temperature (STP), the radiodensity of distilled water is defined as zero Hounsfield units (HU), the radiodensity of air at STP is defined as -1000 HU, blood and other tissues have a positive HU, fat has a negative HU. This method can be used to differentiate 256 shades of gray that are indistinguishable to the naked eye<sup>[17]</sup>.

HU values change with varying density of the organ or fluid. HU values are approximately fixed for all tissues in the body. This variability of the HU values depends on the density of the fluid and can be used for diagnosing thrombosis.

Atypical imaging findings in patients with CVST is a direct visualization of a hyperattenuating thrombus in the occluded sinus (dense sinus sign)<sup>[18,19]</sup>. The cord sign, i.e. a direct sign of CVST is defined as a homogeneous, hyperattenuated appearance of thrombosed venous sinus on non-contrast CT scans, and it is caused by the increased attenuation of the thrombotic material in the affected vessels<sup>[20-22]</sup>. These findings can be used in the work-up of patients who are suspected of developing an acute CVST.

HU value for blood ranges from +35 to +60<sup>[23]</sup>. There are studies in which CT attenuation values have been used in the diagnosis of other acute thrombotic conditions in non-enhanced CT<sup>[24,25]</sup>.

Cobelli et al 2005 found similar attenuation values for acute pulmonary emboli (mean,

74.25 HU; range, 57–93 HU) on unenhanced CT scans), and Goldstein et al 2012 found similar HU values for acute abdominal venous thrombosis (mean, 67.12 HU; range, 53–84 HU).<sup>[24,25]</sup> So the same principle can be used to diagnose at-risk patients of acute cortical venous sinus thrombosis on non-enhanced CT.

There are previous pilot studies which have used Hounsfield units of cerebral venous sinuses to diagnose cerebral venous sinus thrombosis (CVST) by using single non-enhanced CT brain<sup>[26-28]</sup>.

As the apparent increase in sinus attenuation can sometimes be misleading and is not always visually picked up, it is more reliable to measure the attenuation of the sinus by measuring HU. Normalization of this increased attenuation by using hematocrit value in the study may further increase the detection of true cases of CVST on non-contrast CT brain.<sup>[27]</sup>

Accurate and prompt diagnosis of cerebral venous thrombosis is crucial because timely and appropriate therapy can reverse the disease process and

significantly reduce the risk of acute complications and long-term sequelae.

So in the setting where only non-contrast CT is available and the patient is needing an urgent diagnosis for further work-up, HU measurement will help to evaluate at-risk patients with CVST.

## II. AIMS AND OBJECTIVES

### Primary objective:

1) To test the utility value of HU measurement in diagnosing acute cerebral venous sinus thrombosis in emergency setup.

### Secondary objectives:

- 1) Correlation of the HU values with biochemically derived values of hematocrit.
- 2) Evaluating the H: H ratio if sensitivity or specificity of study is increased in patients with acute CVST.

## III. MATERIALS AND METHODS

**Study design:** Non-interventional cross-sectional observational study.

**Period of study:** 18 months.

**Setting:** Department of Radio-diagnosis in a Tertiary care teaching hospital.

**Approximate subjects:** approximately 200 patients were studied over a period of 18 months.

### Inclusion criteria for cases:

Any adult patient who underwent CT scan as advised by their respective physician/surgeon and is suspected to have acute cerebral venous sinus thrombosis and fulfilling the below-mentioned criteria:

- Any sex, male or female.
- Age more than 18 years.
- Patients having normal serum creatinine value (0.3–1.4 mg/dl).



- Patients non-allergic to contrast.
- Patient having registration at this institute.

All patients suspected to have acute CVST were included in the study, irrespective of thrombosis on CT venography.

**Exclusion criteria:**

- Any patient not willing for the study.
- Any patient having increased serum creatinine levels ( $>1.4$  mg/dl).
- Any pregnant female patients.
- Any patient having a history of contrast allergy reaction.
- Cases of intracranial hemorrhage or skull fracture adjacent to dural sinuses.
- An increased intracranial pressure condition such as hydrocephalus, severe brain swelling, intra-axial or extra-axial mass, recent interventional or surgical treatment.
- Intra-venous or intra-arterial iodinated contrast media administration within the previous 24 hr.

**Ethics:**

Proper informed consent was taken from the patient or from relative if the patient was not competent to give consent (in case of altered sensorium) after explaining to them about risks and benefits of examination.

**Study Procedure:**

All CT scans which were assessed for the study were performed on Philips 64 slice Brilliance Compute Tomography scanner. All the clinically suspected patients of CVST were scanned

with NCCT brain plus venography. The serum creatinine value of patient was checked.

CT data were obtained with the following parameters: Field of view: 250 mm  
Slice thickness: 5 mm

Increment: 5 mm Filter: Standard (B)  
Window: C:60 and W:360

Matrix: 512

A weight-based low-dose CT protocol (120 kVp, 1000 mAs) was used. Scanning was performed from top of the skull to base of the skull. CT was performed in the cranio-caudal direction.

CT Venography was performed 45s after administration of intravenous iodinated contrast at 3-4 mL/s with approx. 70-80 cc of contrast injection.

All the image data were analyzed at the workstation (Philips Tera-recon).

All the study related data of suspected patients of acute CVST like HU values of superior sagittal sinus, both transverse sinuses, torcula was obtained and

maximum HU of among these sinuses was recorded. HU value measurement was done by using circle regions of interest (ROI) method on axial or coronal sections. The ROI was set to a limit of 1-30 mm<sup>2</sup> and used a circular ROI area as large as possible that could be measured and if HU values were in decimals then they were rounded off to a closest whole number. (image 17A, B, C)

CT venography scan was assessed for the presence of features of venous sinus thrombosis. The CT findings were recorded in a record form.




Image17 A, B, C: Axial and coronal sections of unenhanced CT scan showing a method of measurement of HU using ROI's in SSS, transverse sinus and torcula respectively



Before the scan, essential clinical history was obtained along with the hematocrit values of those patients in whom serum hematocrit test was done for another purpose. Blood collection was not done specifically for the study purpose. Hematocrit values were recorded. HU: hematocrit ratio was calculated.

**Statistical analysis:**

We made two groups with patients in whom the diagnosis of CVST was excluded on CT venography as a control group.

Maximum HU value amongst the four sinuses (both transverse sinuses, SSS and torcula) of the individual subject from the CVST patient group and the control group was used for the statistical evaluation.

We compared both groups based on HU values and H: H ratio by Mann Whitney U test and unpaired t-test. A p-value < 0.05 was considered to be statistically significant.

Simple regression analysis was used to evaluate the correlation between mean HU and hematocrit.

Based on the collected data, specificity and sensitivity of both HU and H: H ratio for diagnosing acute CVST were calculated with CT venography as a gold standard test.

Receiver operating characteristic (ROC) curves were drawn to define the optimal cutoff value of HU and H: H ratio for which sensitivity and specificity were calculated.

Statistical analyses were done using software IBM SPSS V23 and Microsoft Excel 2013.

**IV. RESULTS**

Results are divided into following sections

**1. Demography**

- a) Age distribution
- b) Gender distribution
- c) Symptom wise distribution
- d) Acute CVST on CT venography amongst total, male and female study population

- e) Sinus wise distribution

**2. Comparison of normal group and disease group by Mann Whitney U test and unpaired t-test in total, male and female study population based on**

- a) Age
- b) Hematocrit
- c) HU
- d) H: H ratio

**3. Simple regression analysis and scatter plot**

- a) Max. HU vs. hematocrit
- b) H: H ratio vs. max. HU

**4. Sensitivity, specificity, PPV, NPV of**

- a) HU
- b) H: H ratio

**5. Receiver operating characteristic (ROC) curve to determine the cut-off value**

- a) Sensitivity vs. false positive of HU
- b) Sensitivity vs. false positive of H: H ratio

**1. DEMOGRAPHY**

The study was conducted over a period of 18 months. 200 patients who had headache associated with other symptoms like seizure, vertigo and drowsiness were included in the study and investigated with non-enhanced CT and CT venography.


**Age Distribution**

Below table 6 and graph 1 show

- Age of the patients included in the study ranged from 18 years to 69 years.
- Mean age was 38 years.
- Maximum number of patients were in the age group 30-50 years (51%).
- Minimum number of patients were in the age group >50 years (19%).

AGE GROUP (YEARS)	NO. OF PATIENTS	PERCENTAGE
<30	60	30%
30-50	102	51%
>50	38	19%

Table 6: showing age wise distribution of total patients with the percentage in three groups.



Graph1: Bar diagram showing agedistribution among the study population.


### GENDER DISTRIBUTION

Below table 7 and graph 2 show

- Out of the 200 study patients, 104 (52%) were males and 96 (48%) were females.
- The overall male to female ratio was 1.083:1.

GENDER	NO OF PATIENTS	PERCENTAGE
MALE	104	52%
FEMALE	96	48%

Table 7: showing gender-wise distribution of total patients with a percentage.



Graph 2: Pie diagram showing gender distribution among the study population.



**AGEWISE GENDER DISTRIBUTION**


Table 8 and graph 3 show

- Out of 60 patients in the age group of <30 years, 36 were males and 24 were females.
- Out of 102 patients in the age group of 30-50 years, 49 were males and 53 were females.

- Out of 38 patients in the age group of >50 years, 19 were males and 19 were females.
- Both male and female patients who were suspected of acute CVST, maximum male and female patients were in 30-50 years age group.

AGE GROUP (YEARS)	MALE	FEMALE	TOTAL
<30	36	24	60
30-50	49	53	102
>50	19	19	38

Table 8: showing age wise gender distribution of total patients.



Graph 3: Bar diagram showing age wise gender distribution among the study population

**SYMPTOMWISE DISTRIBUTION OF STUDY POPULATION**


Headache was the most common clinical symptom in the study population. It was present in all 200 patients. Headache was associated with other symptoms like seizures, vertigo, and drowsiness.

Among 200 patients with headache who were suspected for acute CVST, seizures were present in 93 patients (46.5%), followed by drowsiness (74 patients: 37%), followed by vertigo (33 patients: 16.5%). (Below table 9 and graph 4)

**SYMPTOMWISE DISTRIBUTION**

SYMPTOMS	NO OF PATIENTS	PERCENTAGE
SEIZURES	93	46.5%
VERTIGO	33	16.5%
DROWSINESS	74	37%

Table 9: showing symptom wise distribution of total patients.




Graph4: Pie diagram showing symptom wise distribution of patients among the study population

**ACUTE CVST PATIENTS ON CT VENOGRAPHY AMONGST STUDY POPULATION**  
 Below table 10a and graph 5a show

Out of 200 total patients who were suspected of having acute CVST, 56 patients (28%) had acute thrombosis in either one or two cortical venous sinuses.

ACUTE CVST ON CT VENOGRAPHY	NO OF PATIENTS	PERCENTAGE
YES	56	28%
NO	144	72%

Table 10a: showing acute CVST on CT venography among the total study population.



Graph 5a: Pie diagram showing patients with acute CVST on CT venography among the study population

**GENDER WISE DISTRIBUTION OF ACUTE CVST PATIENTS ON CT VENOGRAPHY**  
 Below table 10b and graph 5b show


Out of total of 56 patients with acute CVST on CT venography, 32 (57%) patients were male and 24 (43%) were female.





ACUTE CVSTON CT VENOGRAPHY	NO OF PATIENTS	PERCENTAGE
MALE	32	57%
FEMALE	24	43%

Table 10b: showing gender-wised distribution of acute CVST on CT venography amongst the total study population.




Graph 5b: Pie diagram showing gender-wised distribution in patients with acute CVST on CT venography.

ACUTE CVST PATIENTS ON CT  
 VENOGRAPHY AMONGST MALE  
 STUDY POPULATION

Below table 11 and graph 6 show  
 Out of total 104 male patients, 32 patients (30%) had acute  
 CVST on CT venography.

ACUTE CVSTON CT VENOGRAPHY	NO OF MALE PATIENTS	PERCENTAGE
YES	32	30%
NO	72	70%

Table 11: showing acute CVST on CT venography amongst male study population.



Graph6: Pie diagram showing patients with acute CVST on CT venography among the male study population.




**ACUTE CVST PATIENTS ON CT VENOGRAPHY AMONGST FEMALE STUDY POPULATION**


Below table 12 and graph 7 show Out of total 96 female patients, 24 patients (25%) had acute CVST on CT venography.

ACUTE CVST ON CT VENOGRAPHY	NO OF FEMALE PATIENTS	PERCENTAGE
YES	24	25%
NO	72	75%

Table 12: showing acute CVST on CT venography amongst female study population.



Graph 7: Pie diagram showing patients with acute CVST on CT venography amongst the female study population. Below the bar diagram (Graph 8) shows patients of cerebral venous sinus thrombosis on CT venography in male and female study population.



Graph 8: bar diagram showing patients with acute CVST on CT venography amongst total, male and female the population.



### SINUS INVOLVEMENT


Below table 13 and graph 9 show

Out of 56 patients, 31 patients had involvement of SSS, 21 had involvement of right transverse sinus, 13 of left transverse sinus and 2 patients had involvement of torcula.

Thus, out of 56 patients presenting with acute CVST 31 i.e. 46% patients had SSS involvement, 31% had left transverse sinus thrombosis, 20% had right transverse sinus thrombosis, 3% had thrombosis of torcula.

SINUS INVOLVEMENT	Number of patients	PERCENTAGE
SSS	31	46%
LEFT TRANSVERSE SINUS	21	31%
RIGHT TRANSVERSE SINUS	13	20%
TORCULA	2	3%

Table 13: showing sinus wise distribution of acute CVST patients.



Graph 9: Bar diagram showing sinus wise distribution of acute CVST patients.



## 2. COMPARISON OF TWO GROUPS


### • Comparison of age in two study groups in the total population.

We have taken a total study population (200 patients) as patients who were suspected of having acute CVST based on clinical symptoms.

On the basis of CT venography findings, we have divided these 200 patients into diseased i.e. patients with acute CVST and into normal i.e. patient without CVST.

On comparison of total population between two groups i.e. patients with thrombosis (disease patients group) and patients without thrombosis (normal patients group) at baseline (Graph 10), Two groups were compared by the **Mann-Whitney U test with p-value = 0.391**.

By comparing two groups i.e. normal and disease for age, both groups did not differ by age significantly. So both groups were comparable.




Graph 10: Bar diagram showing a comparison of age between two groups by Mann-Whitney U test with p-value = 0.391 in total population with mean  $\pm$ SD.

### • Comparison of hematocrit in two study groups in the total population.

For hematocrit values, both disease and the normal group were compared by **Mann-Whitney U test**. As p-

value was 0.07186 ( $>0.05$ ), both the groups did not differ significantly in hematocrit values. (Graph 11), So we have compared both the groups by HU, HU: hematocrit ratio (HH ratio) in the total study population, male study population and in the female study population.




Graph 11: Bar diagram showing a comparison of hematocrit values between two groups by Mann-Whitney U test with p-value = 0.07186 with mean  $\pm$ SD.



- **Comparison of HU between two groups in the total population.**  
Below graph 12 shows  
After comparing age between two groups in the total population, HU values between the two groups were compared by the Mann-Whitney U test with p-value was

HU <0.0001.

On comparing two groups for HU, it has been found that HU value was significantly higher in the disease group as compared to the normal group.




Graph 12: Bar diagram showing a comparison of HU between two groups in total population by Mann-Whitney U test with p-value <0.0001 with mean ±SD.

- **Comparison of H:H ratio between two groups in the total population.**  
Below graph 13 shows  
After comparing hematocrit between two groups in the total population, HU:Hematocrit ratio between two

groups was compared by the Mann-Whitney U test with p-value was <0.00001.

On comparing two groups for HU:Hematocrit ratio, it has been found that HU:Hematocrit ratio was significantly higher in the disease group as compared to the normal group.



Graph 13: Bar diagram showing a comparison of HU:Hematocrit ratio between two groups in total population by Mann-Whitney U test with p-value <0.00001 with mean ±SD.




- **Comparison of age between two groups in the male study population.**

Both groups were compared for age by Mann Whitney U test with p value = 0.1556

Below bar diagram (graph 14) shows that mean age in male patients with

disease group was 35.18 yrs (range was between 30-66 yrs and SD of 11.33 yrs).

Also, mean age in the normal male study population was 39.15 yrs (range was between 19-69 yrs and SD of 12.91 yrs)




Graph 14: bar diagram showing a comparison of age by Mann Whitney test with p value = 0.1556 with mean, range and SD of disease group and control group in the male study population.

- **Comparison of hematocrit between two groups in the male study population.**

Both groups were compared for hematocrit by Mann Whitney U test with p value = 0.13. So both groups didn't differ significantly for hematocrit and so were comparable.

Below the bar diagram (graph 15) shows that mean hematocrit in male patients with disease group was 42.71% (range was between 30-50% and SD of 3.48%).

Also, mean age in the normal male study population was 44.8% (range was between 40-59% and SD of 3.66%)



Graph 15: bar diagram showing a comparison of hematocrit by Mann Whitney test with p value = 0.13 with mean, range and SD of disease group and control group in the male study population.



- **Comparison of HU between two groups in the male study population.**

HU values between two groups in the male study population were compared by

**Mann-Whitney U test with p-value was <0.0001.**


Below graph (graph 16) shows that HU value was significantly higher in the disease group as compared to the normal group in the male population.

Mean HU in the diseased group was 68.37 (range: 48-78 and SD: 6.28) and in normal

group was 47.79 (range: 39-68 and SD: 5.17)

Below the bar diagram (graph 15) shows that mean hematocrit in male patients with disease group was 42.71% (range was between 30-50% and SD of 3.48%).

Also, mean age in the normal male study population was 44.8% (range was between 40-59% and SD of 3.66%)



Graph 15: bar diagram showing a comparison of hematocrit by Mann Whitney test with p value=0.13 with mean, range and SD of disease group and control group in the male study population.

- **Comparison of HU between two groups in the male study population.**

HU values between two groups in the male study population were compared by


**Mann-Whitney U test with p-value was <0.0001.**

Below graph (graph 16) shows that HU value was significantly higher in the disease group as compared to the normal group in the male population.

Mean HU in the diseased group was 68.37 (range: 48-78 and SD: 6.28) and in normal

group was 47.79 (range: 39-68 and SD: 5.17)





Graph 16: bar diagram showing a comparison of HU value by Mann-Whitney test with  $p$ -value  $< 0.0001$  with mean, range and SD in the disease group and in a control group of the male study population.


- **Comparison of H:H ratio between two groups in the male population.**

HU: hematocrit values between two groups in the male study population were compared by **Mann-Whitney U test with  $p$ -value  $< 0.00001$ .**

Below graph (graph 17) shows that HU: hematocrit

value was significantly higher in the disease group as compared to the normal group in the male population.

Mean value of HU: hematocrit ratio in the diseased group was 1.6 (range: 1.2-1.8 and SD: 0.11) and in the normal group was 1.08 (range: 0.96-1.55 and SD: 0.11).



Graph 17: Bar diagram showing a comparison of HU: Hematocrit ratio by




MannWhitneyUtestwithapvalue<0.00001betweentwogroupsinafemalepopulationwithmean  $\pm$ SD.

- **Comparison of age between two groups in the female study population.**

We have compared age distribution between disease group and normal group in female population by **unpaired t-test** with p-value of  $>0.05$

Below the bar diagram (graph 18) shows that the mean age in female patients with disease group was 38.75 yrs (range is between 24-56 yrs and SD of 8.9 yrs). Also, mean age in the normal female study population was 38.36 yrs (range is between 18-69 yrs and SD of 12.72 yrs).




Graph 18: bar diagram showing a comparison of age by unpaired t-test with p-value  $>0.05$  with mean, range and SD of disease group and control group in the female study population.

- **Comparison of hematocrit between two groups in the female study population.**

Both groups were compared for hematocrit by MannWhitneyUtest with p-value = 0.053. So both groups didn't differ significantly for hematocrit and so were comparable. Below bar diagram (graph 19) shows that mean hematocrit

in female patients with disease group was 40.2% (range was between 36-45% and SD of 2.78%). Also, mean age in the normal female study population was 41.98% (range was between 35-53% and SD of 3.85%).



Graph 19: bar diagram showing a comparison of hematocrit by Mann Whitney test with p value=0.053 with mean, range and SD of disease group and control group in the female study population.

- **Comparison of HU between two groups in the female study population.**


HU values between two groups in the female study population were compared by

**Mann-Whitney U test with p-value was <0.0001.**

Below graph (graph 20) shows that HU value was signifi

cantly higher in the disease group as compared to the normal group in the female population.

Mean HU in the disease group was 67.13 (range: 61-75 and SD: 3.8) and in the normal group was 47.24 (range: 37-76 and SD: 5.44).



Graph 20: bar diagram showing a comparison of HU value by Mann Whitney U test with p-value <0.0001 with mean, range and SD in the disease group and in control group of the female study population.




• **Comparison of HU: hematocrit between two groups in the female study population.**

HU: hematocrit values between two groups in the female study population were compared by Mann-Whitney U test with p-value was <0.00001.

Below graph (graph 21) shows that HU: hematocrit value was significantly higher

in the disease group as compared to the normal group in the female population.

Mean value of HU: hematocrit ratio in the disease group was 1.67 (range: 1.48-1.92 and SD:0.099) and in the normal group was 1.13 (range: 0.85-1.95 and SD:0.15).



Graph 21: Bar diagram showing a comparison of HU: Hematocrit ratio by Mann-Whitney U test with p-value <0.00001 between two groups in the female population with mean ± SD.

**3. SIMPLE REGRESSION ANALYSIS AND SCATTER PLOT**

Linear regression analysis for max. HU and hematocrit

Below table 14 shows

By applying linear regression test, in total diseased popu

lation, change in HU value was contributed by hematocrit by 37%.


In male diseased population, change in HU value was contributed by hematocrit by 41%.

In female diseased population, change in HU value was contributed by hematocrit by 30%.

	DISEASE POPULATION		
	TOTAL	MALE	FEMALE
<b>R VALUE</b>	<b>0.61</b>	<b>0.64</b>	<b>0.55</b>
<b>p VALUE</b>	<b>&lt;0.0001</b>	<b>0.0001</b>	<b>0.0053</b>
<b>R<sup>2</sup></b>	<b>0.37</b>	<b>0.41</b>	<b>0.30</b>

Table 14: coefficient of correlation, p-value and R<sup>2</sup> value in disease population for max. HU and hematocrit.


Below graph (graph 22) states that there was a significant positive correlation between the hematocrit value and attenuation of sinuses (HU value) in disease group with a coefficient of correlation, r(54)=0.61 and with p<0.0001.



Graph 22: Scatter diagram showing a correlation of max. HU of sinus v/s hematocrit DISEASE group (n=56).




Below graph (graph 23) states that there was a significant positive correlation between the hematocrit value and attenuation of sinuses (HU value) in a normal group with  $r(142)=0.3$  and  $p<0.0002$ .



Graph 23: Scatter diagram showing a correlation of max. HU of sinus v/s hematocrit in NORMAL group (n=144).


Below graph (graph 24) shows that there was a significant positive correlation between the attenuation of sinuses (HU value) and HU:hematocrit ratio in disease group with  $r(54)=0.41$  and  $p<0.0015$ .



Graph 24: Scatter diagram showing a correlation of HU: hematocrit ratio of sinus v/s max. HU in DISEASE group (n=56).



Below graph (graph 25) states that there was a significant positive correlation between the attenuation of sinuses (HU value) and HU:hematocrit ratio in a normal group with  $r(142)=0.71$  and  $p<0.0001$ .




Graph 25: Scatter diagram showing correlation of HU: hematocrit ratio of sinus v/s max.HU in NORMAL group (n=144).

**4. SENSITIVITY, SPECIFICITY, PPV, NPV OF HU AND H:H RATIO** Calculation of sensitivity, specificity based on HU value in the total population

Below graph 26 and table 15 show sensitivity and specificity in percentage (%) of max.HU in total population 96.42, 96.52 respectively.

Based on HU value	
TOTAL POPULATION (n=200)	
SENSITIVITY (Sn)	96.42
SPECIFICITY (Sp)	96.52
POSITIVE PREDICTIVE VALUE (PPV)	91.52
NEGATIVE PREDICTIVE VALUE (NPV)	98.58

Table 15: sensitivity, specificity, PPV, NPV of HU value in diagnosing Acute CVST in the total population.




Graph 26a: Bar diagram showing Sensitivity, Specificity, PPV, NPV of max.HU in Percentage (%) for diagnosis of Acute CVST in Total population (n=200).

**Calculation of sensitivity, specificity based on HU value in the male population**

Below graph 26b and table 15b shows sensitivity and specificity in percentage (%) of max.HU in male population 93.75, 95.84 respectively.

Based on HU value	
MALE POPULATION (n=104)	
SENSITIVITY (Sn)	93.75
SPECIFICITY (Sp)	95.84
POSITIVE PREDICTIVE VALUE (PPV)	90.9
NEGATIVE PREDICTIVE VALUE (NPV)	97.18

Table 15b: sensitivity, specificity, PPV, NPV of HU value in diagnosing Acute CVST in the male population.



Graph 26b: Bar diagram showing Sensitivity, Specificity, PPV, NPV of max.HU in Percentage (%) for diagnosis of Acute CVST in Male population (n=104).






**Calculation of sensitivity, specificity based on HU value in the female population**

Below graph 26c and table 15c shows sensitivity and specificity in percentage (%) of max. HU in female population 100, 97.23 respectively.

Based on HU value	
FEMALE POPULATION (n=96)	
SENSITIVITY (Sn)	100
SPECIFICITY (Sp)	97.23
POSITIVE PREDICTIVE VALUE (PPV)	92.3
NEGATIVE PREDICTIVE VALUE (NPV)	100

Table 15c: sensitivity, specificity, PPV, NPV of HU value in diagnosing Acute CVST in the female population.



Graph 26c: Bar diagram showing Sensitivity, Specificity, PPV, NPV of max. HU in Percentage (%) for diagnosis of Acute CVST in female population (n=96)


**Calculation of sensitivity, specificity based on HU: hematocrit ratio (H:H) in the total population**

Graph 27a and table 16a shows sensitivity and specificity in percentage (%) of H:H ratio in total population of 96.42, 97.91 respectively.

Based on H:H ratio	
TOTAL POPULATION (n=200)	
SENSITIVITY (Sn)	96.42
SPECIFICITY (Sp)	97.91
POSITIVE PREDICTIVE VALUE (PPV)	94.73
NEGATIVE PREDICTIVE VALUE (NPV)	98.6



Table 16a: sensitivity, specificity, PPV, NPV of H:H ratio in diagnosing Acute CVST in the total population.




Graph 27a: Bar diagram showing Sensitivity, Specificity, PPV, NPV of H:H ratio in Percentage (%) for diagnosis of Acute CVST in Total population (n=200).

**Calculation of sensitivity, specificity based on H:H ratio in the male population**

Graph 27b and table 16b show sensitivity and specificity in percentage (%) of H:H ratio in male population 93.75, 97.23 respectively.

Based on H:H ratio	
MALE POPULATION (n=104)	
SENSITIVITY (Sn)	93.75
SPECIFICITY (Sp)	97.23
POSITIVE PREDICTIVE VALUE (PPV)	93.75
NEGATIVE PREDICTIVE VALUE (NPV)	97.23

Table 16b: sensitivity, specificity, PPV, NPV of H:H ratio in diagnosing Acute CVST in the male population.



Graph 27b: Bar diagram showing Sensitivity, Specificity, PPV, NPV of H:H ratio in Percentage (%) for




thediagnosisofAcute CVSTinTotalpopulation(n=104).

**Calculationofsensitivity,specificitybasedonHU:haematocritratio(H:H)inthefemalepopulation**

Graph27candtable16cshowsensitivityandspecificityinpercentage(%)ofH:Hratioinfemalepopulation100,98.62respectively.

BasedonH:Hratio	
FEMALEPOPULATION(n=104)	
SENSITIVITY(Sn)	100
SPECIFICITY(Sp)	98.62
POSITIVEPREDICTIVEVALUE(PPV)	96
NEGATIVEPREDICTIVEVALUE(NPV)	100

Table16c:sensitivity,specificity,PPV,NPVofH:Hratio indiatingAcuteCVSTinthemale population.



Graph 27c: Bar diagram showing Sensitivity, Specificity, PPV, NPV of H:H ratio inPercentage(%)fordiagnosisof AcuteCVSTin femalepopulation(n=96).


So after comparing both sensitivity and specificity for max. HU and H:H ratio fordiagnosing acute CVST patients, it was found that specificity is more if we use H:Hratio as a parameter for diagnosing patients with acute CVST with sensitivity for bothremainingthesame.

So in simple words, we can rule out true negative patients out of suspected acuteCVSTpatientsmoreefficientlywithH:Hratiorat herthanusing sinusattenuation(HU)alone.

**5. Receiver operating characteristic (ROC) curve for calculation of the cut-offvalue**

- ROCcurveofsensitivityvs.falsepositive formax.HU


ThevaluewhichismarkedwithredinbelowROCcurve(graph28)suggeststhat sinusattenuationvalue(HU)of61ormorewasmoresensitive(96.42%)indiagnosingacuteCVSTcaseswithsmallfalsepositiverate(3.4%).



Graph 28: receiver operating characteristic (ROC) curve showing Sensitivity and 1-Specificity (false positive) of maximum HU for the diagnosis of Acute CVST in the total population (n=200).

• ROC curve of sensitivity vs. false positive for H:H ratio

The value which is marked with red in above ROC curve (graph 29) suggests that H:H ratio of 1.487 or more was more sensitive (96.42%) in diagnosing acute CVST cases with small false positive rate (2%).



Graph 29: receiver operating characteristic (ROC) curve showing Sensitivity and 1-Specificity (false positive) of H: H ratio for the diagnosis of Acute CVST in the total population (n=200).



Sample cases with HU values of SSS, transverse sinuses in patients with and without acute CVST (fig 18,19,20).




Image 18 A and B: axial sections of CT brains showing normal SSS (A) and hyperattenuating SSS in CVT (B)




Image 19A,B,C: axial section of CT brain showing dense SSS (A) with HU of 64 (B) and CE venography showing corresponding filling defect in SSS (C) / thrombosis.





Image 20A and B: axial sections of CT brain (A) showing HU of 67 in left transverse sinus with a corresponding filling defect in (B) on CT venography of thrombosis.



## V. DISCUSSION

Acute CVST is one of the no so common causes of stroke worldwide with varying clinical scenario. So imaging plays a pivotal role in guiding management.

Both CT and MRI are sensitive imaging modalities when it comes to the detailed evaluation of acute CVST patients with invasive methods like DSA cerebral venography is considered the gold standard. However, due to wide spread availability, lower cost, faster scanning times, and completion of NCCT, CT venography within 5-7 minutes as well as the fact that many patients are in drowsiness or altered sensorium and movement artifacts will render reading MRI scans less fruitful, CT is still a one-stop shop in cases of imaging of acute CVST. "Hyperattenuating sign" can be observed on non-contrast CT scans when acute thrombus has formed in the venous sinuses. In the literature, this sign was originally found in only a few of patients with CVST and was considered as a non-specific sign. There was a nearly study reported as sensitivity of approximately 25%<sup>[22]</sup>. With thinner CT sections and new advancement, however, this sign was detected much

more frequently. Another study reported as sensitivity of 64% of the dural sinus for CVST<sup>[105]</sup>.

This increase in attenuation is caused by clot retraction, with the elimination of water and causing an increase in the concentration of hemoglobin and red blood cells. This causes an increased attenuation of the thrombus to 60-90 HU.<sup>[106]</sup> Also, interpretation of hyperattenuated sinus only visually can sometimes miss the diagnosis, so calculating HU value by putting ROI in sinuses and measuring attenuation

within sinuses is more helpful in detection of acute CVST.

So our study will be useful in patients who do not have S.creatinine values or patients in whom contrast is contraindicated and in an institution where the only facility of non-contrast CT scan is available. Also, there are similar studies performed in the western population. But no such study has ever been published in the literature for Indian population.

Our study included 200 clinically suspected cases of acute CVST whose CT brain with venography was performed. Scanning was performed from top of the skull to base of the skull and in the cranio-caudal direction. Before the scan, essential clinical history was obtained along with hematocrit values of the patients in whom serum hematocrit test was done for another purpose.

Out of a sample of 200 in the study, sex distribution was of 104 males comprising 52% and 96 females

comprising 48% in the study with all those meeting inclusion criteria were included. Age of the patients included in the study ranged from 18 years to 69 years. Mean age was 38 years. A maximum number of patients were in the age group 30-50 years (51%). Minimum number of patients were in the age group >50 years (19%). In the age group of <30 years, males were more often affected than females and in the age group 30-50 years, female patients were more affected than male. In age group >50 years, there was an equal number of male and female patients.

In our study headache was present in all cases followed by seizures (46.5%), drowsiness (16.5%) and vertigo (37%).

Out of 200 patients of suspected of acute CVST, 56 (28%) patients had the disease on CT venography. Out of these 56 patients, 32 were male and 24 were female.

The most common sinus involved was superior sagittal sinus (46%), followed by left transverse sinus (31%), right transverse sinus (20%) and torcula (3%) was affected in very less number of patients.

For statistical analysis, we divided study population into two groups, disease group (patients with acute CVST on CT venography) and normal i.e. control group (patients without acute CVST on CT venography) and then compared both groups.

Both groups were compared by the Mann-Whitney U test for age and hematocrit values. It was found that both groups didn't differ by both age and hematocrit significantly and were comparable.

We found that on comparing two groups for both HU and H:H ratio, both values were significantly higher in disease group compared to the normal group.

The mean attenuation was 67.84 HU ( $\pm 5.36$ ) in the disease group and 47.51 HU ( $\pm 5.3$ ) in the normal group. In male and female patients with acute CVST mean attenuation was 68.37 HU ( $\pm 6.28$ ) and 67.13 HU ( $\pm 3.8$ ) respectively.

Cobelli et al 2005 found similar attenuation values for acute pulmonary emboli (mean, 74.25 HU; range, 57-93 HU) on unenhanced CT scans,<sup>[24]</sup> and Goldstein et al 2012 found similar HU values for acute abdominal venous thrombosis (mean, 67.12 HU; range, 53-84 HU).<sup>[25]</sup>

Also, there are similar studies in which Buyck et al found that mean attenuation of thrombosed sinuses was 73.9 HU with a threshold of 62 HU which can be used to discriminate patients with acute CVST from patients without.<sup>[106]</sup>

We found that value of H:H ratio was significantly





higher in acute CVST cases with a mean of  $1.64(\pm 0.11)$  and lower in a normal group with a mean of  $1.1(\pm 0.13)$ . In male and female patients with acute CVST mean H:H ratio was  $1.6(\pm 0.11)$  and  $1.67(\pm 0.09)$  respectively. There is no overlap of the H:H ratio distribution in patients with CVST and without CVST.

Black et al found mean H:H values of 2.2 in patients with CVST and 1.44 in patients without CVST and in their study there were only 8 patients with CVST and a cut off value of 1.8.<sup>[27]</sup> The study by Buyck et al found that mean H:H value of  $1.91 \pm 0.32$  in patients with CVST and  $1.33 \pm 0.12$  and a cut off value of 1.52.<sup>[106]</sup> Both studies were retrospective studies, so they were prone to selection bias. Our study is a cross-sectional study, so the chances of selection bias are lesser.

Anemic patients have low hematocrit values and so low HU values even in case of thrombosis. Similarly, conditions in which there is high hematocrit value like polycythemia vera or dehydration, there is high HU value even if there is no thrombosis. These findings are reported and are the most common cause of false positive or false negative results for acute CVST.<sup>[107]</sup> Therefore, to avoid this, HU values have to be correlated with hematocrit values as it corrects for the abnormal HCT level. Hence H:H ratio has been calculated.

In our study, there was a significant and positive correlation between HU and hematocrit values, the coefficient of correlation was 0.61 in patients with acute CVST.

There are similar studies in which Buyck et al<sup>[106]</sup> and Lee et al<sup>[26]</sup> found a significant correlation with both hemoglobin and HCT with HU.

In our study, sensitivity and specificity for HU were 96.42 and 96.52 respectively. Sensitivity and specificity for H:H ratio was 96.42 and 97.91. This minor difference in specificity suggests that HU alone can be a very good substitute if hematocrit values are not available and if we have both values then specificity of diagnosis of acute CVST increases so that there will be lesser false positive results.

We have plotted the receiver operating characteristic (ROC) curves, in which we have found a threshold of 61 HU which can be used to differentiate patients with acute CVST from those without. On the basis of ROC curve for H:H ratio, the value of more than

1.48 suggests a strong likelihood of thrombosis in venous sinuses. So these cutoff or threshold values can help in distinguishing patients with and without acute CVST on non-

contrast CT brain in an emergency setup.

## VI. LIMITATIONS:

This study has some limitations. First, for consistency, the ROIs were measured by a single radiologist, so inter-observer variability for ROI measurement was not included in the study.

Second, the immediate vicinity of the skull to venous sinuses may cause partial volume effects and could have caused false positive higher HU values.

## VII. SUMMARY AND CONCLUSION

The exact prevalence of acute CVST in India is hitherto unknown. The clinical presentation of acute CVST is variable.

It is frequently seen between 35-40 years of age and CVST is slightly more common in women, due to pregnancy, oral contraceptive use and in puerperium in the age group of 20 to 35. Also, many times in acute CVST patients no risk factor is found. It is very important to diagnose and treat CVST in patient with absence of co-morbidities.

Also, prompt and accurate diagnosis of cerebral venous thrombosis is crucial because timely and appropriate therapy can reverse the disease process and significantly can prevent morbid complications and long-term sequelae.

We studied 200 clinically suspected patients of acute CVST who were investigated with CT brain with venography. Our results demonstrated a significant and positive correlation between hematocrit and attenuation values of sinuses.

We found that attenuation values (HU) and H:H ratio values were significantly higher in acute CVST patients than without acute CVST patients. We found a threshold value of HU and H:H ratio above which we can diagnose patients with acute CVST.

In addition to this, we found higher sensitivity and specificity for both HU and H:H ratio in diagnosing acute CVST. Overall specificity of H:H ratio in diagnosing acute CVST was more as compared to HU alone. So the conclusion is that patients who do not have acute CVST are certainly ruled out on the basis of H:H ratio.

This allows accurate pinpointing of acute CVST at an unenhanced CT examination, and we conclude that higher HU value predicts an increased risk of acute CVST in an appropriate clinical scenario.



### BIBLIOGRAPHY

1. Julle M. CLINICAL APPLICATIONS OF VASCULAR IMAGING Cerebral Venous Thrombosis and Multi-detector CT Angiography: Tips and Tricks. 2006;5-19.
2. Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F. Prognosis of Cerebral Vein and Dural Sinus Thrombosis: Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). *Stroke*. 2004;35(3):664-70.
3. Abraham J, Rao PS, Inbaraj SG, Shetty G, Jose CJ. An epidemiological study of hemiplegia due to stroke in South India. *Stroke*. 1(6):477-81.
4. Ameri A, Bousser MG. Cerebral venous thrombosis. *Neurol Clin*. 1992 Feb;10(1):87-111.
5. Villringer A, Mehraein S, Einhüpl KM. Pathophysiological aspects of cerebral sinus venous thrombosis (SVT). *J Neuroradiol*. 1994 Apr;21(2):72-80.
6. Siddiqui FM, Kamal AK. Incidence and epidemiology of cerebral venous thrombosis. *J Pak Med Assoc*. 2006;56(11):485-7.
7. James M, Provenzale M. Nontraumatic Neurologic Emergencies: Imaging Findings and Diagnostic Pitfalls. *Symp A Q J Mod Foreign Lit*. 1998;(2):1323-1325
8. Mahesh R Patel, MD; Chief Editor: James G Smirniotopoulos M. Brain Imaging in Venous Sinus Thrombosis. *medscape*. 2018;1-11.
9. Sharma S, Sharma N, Yeolekar ME. Acute subarachnoid hemorrhage as initial presentation of dural sinus thrombosis. *J Neurosci Rural Pract*. 2010 Jan;1(1):23-5.
10. Etages A, Chan HW. Current intervention strategies for Cerebral Venous Sinus Thrombosis. *Internet J Neurosurg*. 2015; Volume 4 (January 2007): Number 2.
11. Macchi PJ, Grossman RI, Gomori JM, Goldberg HI, Zimmerman RA, Bilaniuk LT. High field MR imaging of cerebral venous thrombosis. *J Comput Assist Tomogr*. 10(1):10-5.
12. McMurdo SK, Brant-Zawadzki M, Bradley WG, Chang GY, Berg BO. Dural sinus thrombosis: study using intermediate field strength MR imaging. *Radiology*. 1986 Oct;161(1):83-6.
13. Khandelwal N, Agarwal A, Kochhar R, Bapuraj JR, Singh P, Prabhakar S, et al. Comparison of CT venography with MR venography in cerebral sinovenous thrombosis. *Am J Roentgenol*. 2006;187(6):1637-43.
14. Ozsvath RR, Casey SO, Lustrin ES, Alberico RA, Hassankhani A, Patel M. Cerebral Venography: Comparison of CT and MR Projection Venography. *Am J Roentgenol*. 1997;169(6):1699-707.
15. Edited by M Hofer. pp. 224, 2007 (Springer-Verlag, Berlin, Heidelberg NY. CT teaching manual: a systematic approach to CT reading (3rd edition). *Br J Radiol*. 2008 Dec;81(972):989-90.
16. Ferro JM, Bousser M-G, Canhão P, Coutinho JM, Crassard I, Dentali F, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. *Eur J Neurol*. 2017 Oct;24(10):1203-13.
17. Bousser MG. Cerebral venous thrombosis: Diagnosis and management. *J Neurol*. 2000;247(4):252-8.
18. Teasdale E. Cerebral venous thrombosis: Making the most of imaging. *JRSoc Med*. 2000;93(5):234-7.
19. Vijay RKP. The Cord Sign. *Radiology*. 2006;240(1):299-300.
20. Virapongse C, CAZENAVE C, QUISLING R, SARWAR M, HUNTER S. The Empty Delta Sign - Frequency and Significance in 76 Cases of Dural Sinus Thrombosis. *Radiology*. 1987;162(3):779-85.
21. Oates ME. *Essential Radiology: Clinical Presentation, Pathophysiology, Imaging*, 2nd ed. *Am J Roentgenol*. 2006 Dec;187(6):W665-W665.
22. Cobelli R, Zompatori M, De Luca G, Chiari G, Bresciani P, Marcato C. Clinical usefulness of computed tomography study without contrast injection in the evaluation of acute pulmonary embolism. *J Comput Assist Tomogr*. 29(1):6-12.
23. Goldstein M, Quen L, Jacks L, Jhaveri K. Acute abdominal venous thromboses - the hyperdense CT sign. *J Comput Assist Tomogr*. 2012;36(1):8-13.
24. Lee SY, Cha SH, Lee SH, Shin DI. Evaluation of the effect of hemoglobin or hematocrit level on dural sinus density using unenhanced computed tomography. *Yonsei Med J*. 2013;
25. Black DF, Rad AE, Gray LA, Campeau NG, Kallmes DF. Cerebral venous sinus density on noncontrast CT correlates with hematocrit. *Am J Neuroradiol*. 2011;32(7):1354-7.
26. Buyck PJ, De Keyser F, Vanneste D, Wilms G, Thijs V, Demaere P. CT Density Measurement and



- dH:HRatioAreUsefulinDiagnosingAcuteCerebralVenous SinusThrombosis.*AmJNeuroradiol.*2013 Aug;34(8):1–5.
27. HealyJF,NicholsC.Polycythemiainmimickingvenousinusthrombosis.*AmJNeuroradiol.*2002 ;23(8):1402–3.